Fractyl Health (GUTS) News
NASDAQ: GUTSHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GUTS news summary
We found 10 recent headlines mentioning Fractyl Health (GUTS): 1 in the past week and 5 in the past 30 days, most often from Nasdaq, GlobeNewswire, PR Newswire. GUTS is making an outsized move today, down 14.16% at $0.82, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Fractyl Health, Inc. Discloses Separation and Consulting Agreements with Former President Jay Caplan", was published by Nasdaq on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Fractyl Health headlines
- Fractyl Health, Inc. Discloses Separation and Consulting Agreements with Former President Jay CaplanFractyl Health, Inc. filed an amendment to disclose the material terms of a Separation Agreement and Release and a Consulting Agreement entered into with Jay Caplan, who retired from the Company as…Nasdaq
- Fractyl Health, Inc. Reports Third Quarter 2026 Financial Results and Business UpdatesFractyl Health, Inc. announced its third quarter 2026 financial results and a strategic reprioritization to focus on its Revita program. On October 21, 2026, the company adopted a plan to sharpen its…Nasdaq
- Fractyl Health (GUTS) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel…GlobeNewswire
- Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential CommercializationBURLINGTON, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel…GlobeNewswire
- Fractyl Health Consensus Price Target Increased by 917.27% to $46.07The average one-year price target for Fractyl Health (NASDAQGM:GUTS) has been revised to $46.07 / share. This is an increase of 917.27% from the prior estimate of $4.53 dated September 29, 2026.…Nasdaq
- Fractyl Health, Inc. Announces Strategic Reprioritization, 45% Workforce Reduction, and Leadership ChangesFractyl Health, Inc. adopted a plan on October 21, 2026, to sharpen its strategic focus on its Revita program in connection with a strategic reprioritization. As part of the plan, the company will…NasdaqGUTS, LEN.B
- Pre-Market Most Active for Oct 16, 2026 : TSLL, GUTS, NOK, VRNS, TQQQ, TSLA, SPCX, STLA, IONQ, BAC, LYG, JOBYThe NASDAQ 100 Pre-Market Indicator is down -44.48 to 29,891.11. The total Pre-Market volume is currently 108,987,769 shares traded.The following are the most active stocks for the pre-market…NasdaqTSLL, GUTS, NOK, VRNS
- Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 DiscontinuationREMAIN-1 met its six-month co-primary endpoint with high statistical significance (p=0.0023; mITT population); demonstrated 80% retention of GLP-1 induced weight loss vs 67% for shamGlobeNewswire
- Robbins LLP Reminds Fractyl Health, Inc. Stockholders of the October 20, 2026 Lead Plaintiff Deadline - GUTS Investors Should Contact the Firm for Information About Leading the Class ActionSAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise…PR Newswire